Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity ... clinical development of stenoparib toward FDA approval in advanced ovarian cancer. With this new phase 2 protocol ...

Future Market Insights (FMI), a leading provider of industry analysis and market research, has unveiled its latest report highlighting the impressive growth trajectory of the global advanced ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Allarity Therapeutics, Inc. has announced plans to advance the clinical development of stenoparib, a dual PARP/Wnt pathway inhibitor, for FDA approval in advanced ovarian cancer. The new Phase 2 ...

German healthcare and technology group Merck KGaA (MKGAY) is in advanced talks to acquire U.S. cancer and rare disease drugmaker Springworks Therapeutics (SWTX), people familiar with the matter ...

endpoints for patients with advanced gastric cancer. The disappointing outcome has led the company to halt plans for Phase 3 studies in this indication. Leap Therapeutics reported that while the ...

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Amidst the increasing incidence of blood cancer cases, Qartemi—a pioneering CAR-T cell therapy from Immuneel Therapeutics—stands as a lifeline, representing the need for advanced treatment in ...

I have two solutions to help the Canadiens win games: Martin St-Louis could shave his beard to reverse the bad luck (I don’t wish for him to go that far) The Canadiens could play in a parallel ...

Why does he say that? Because as reported this morning by Anthony Marcotte on BPM Sports, St-Louis argued yesterday that based solely on advanced stats, the CH would have won four of their last ...

VISTA is currently enrolling. NCT04850118. Beacon Therapeutics is an ophthalmic gene therapy company founded to save and restore the vision of patients with a range of prevalent and rare retinal ...